Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LUYE PHARMA GROUP LTD.

綠 葉 製 藥 集 團 有 限 公 司

(Incorporated in the Bermuda with limited liability)

(Stock Code: 02186)

VOLUNTARY ANNOUNCEMENT ON-MARKET REPURCHASE OF SHARES

This announcement is made by Luye Pharma Group Ltd. (the ''Company'') on a voluntary basis.

The board of directors (the ''Board'') of the Company announces that the Company on 4 September 2017 repurchased on The Stock Exchange of Hong Kong Limited (the ''Stock Exchange'') 6,637,500 ordinary shares of the Company pursuant to the repurchase mandate (the ''Repurchase Mandate'') granted by the shareholders of the Company (the ''Shareholders'') to the Board at the annual general meeting of the Company held on 13 June 2017. The Company will subsequently cancel the repurchased shares.

Currently, the cash flow from operational activities of the Company is strong and healthy. The Board believes the share repurchase and subsequent cancellation of the repurchased shares can improve the return to shareholders. The share repurchase also reflects the confidence of the Board in the prospects of the Company. The Company may or may not make further share repurchases. Shareholders and investors should note that whether the Company will make any further share repurchases by the Company under the Repurchase Mandate or not will be subject to market conditions and the Board's absolute discretion. There is no assurance of the timing, quantity or price of any share repurchases or whether the Company will make any further share repurchases at all.

Shareholders and investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board

LUYE PHARMA GROUP LTD.

Liu Dian Bo

Chairman

Hong Kong, 4 September 2017

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive Director of the Company is Mr. SONG Rui Lin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.

Luye Pharma Group Ltd. published this content on 04 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 05 September 2017 02:52:06 UTC.

Original documenthttp://www.luye.cn//lvye_en/uploads//2017-09/05/_1504579538_pnwo63.pdf

Public permalinkhttp://www.publicnow.com/view/CEF6C7892ACD552E11FDC4DFD7E092921379B7F3